Clinical research generates evidence about how investigational or marketed products affect human health, through studies that test safety, dosing and effectiveness. Regulatory affairs manages the relationship between a sponsor and government health authorities, preparing submissions, interpreting rules and maintaining approvals. The two areas depend on each other. Research data are only useful if they are collected to standards that regulators accept, and regulatory strategy shapes which studies are needed. For example, a sponsor planning a new drug application must design trials that answer the questions the agency will ask, so research and regulatory professionals plan together from the earliest stages of development.
Clinical development is usually described in phases. Early studies in small groups of healthy volunteers or patients focus on safety, tolerability and how the body processes a compound. Later phases enroll larger patient groups to assess whether the product works for a defined condition and to identify common side effects. Confirmatory studies then compare the product with standard care in broader populations, producing the evidence regulators weigh for approval. Post-approval studies continue monitoring safety in routine use. Each phase answers a different question, and sponsors must justify the transition from one phase to the next using the data from the previous stage.
Good Clinical Practice is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials involving human subjects. It requires that the rights, safety and wellbeing of participants take priority over other interests, and that data are credible, accurate and verifiable. Sponsors are responsible for trial design, oversight of contractors and safety reporting. Investigators must protect participants, follow the protocol and keep complete source records. Monitors verify that trial conduct and data match the source documents. Adherence to these principles is what allows regulators to accept trial data across different countries, so it is a practical requirement as well as an ethical one.
A clinical trial protocol is the detailed plan that describes the study's objectives, design, eligibility criteria, interventions, outcome measures, statistical methods and safety procedures. It should state the primary endpoint clearly and explain how sample size was calculated so the study has enough power to answer its main question. Inclusion and exclusion criteria define who may participate and protect vulnerable people from inappropriate enrollment. The protocol also sets rules for handling adverse events and deviations. Ethics committees and regulators review the protocol before a study begins, and every site follows it, so a well-written protocol reduces ambiguity, supports reproducibility and makes later data interpretation far more defensible.
Informed consent is a process rather than a single signature. Participants must receive information about the study purpose, procedures, expected duration, risks, potential benefits, alternatives to participation and their right to withdraw without penalty. The information should be written in plain language, with time for questions. The investigator or a delegated staff member must confirm understanding, and the person must be free from coercion or undue influence. Special safeguards apply to people who may have limited capacity, children and vulnerable groups. Consent forms must be approved by an ethics committee, and the signed record and any re-consent when protocols change are kept as part of the trial documentation.
An institutional review board, or independent ethics committee, is a group that reviews research involving people to protect their rights and welfare. Before a study starts, it evaluates the scientific design, the risk to participants relative to expected benefit, the selection of subjects, the adequacy of the consent materials and the arrangements for privacy and compensation. It may request changes or reject a proposal. During the study it reviews safety reports, protocol amendments and any serious problems, and it can suspend or terminate research that is unsafe. Because the committee's independence is central to public trust, its members should have no financial stake in the outcome of the study.
A regulatory submission for a new medicine gathers the evidence needed for a health authority to judge its quality, safety and efficacy. In many regions it follows a common structure called the Common Technical Document, divided into modules covering administrative information, summaries, quality data on manufacturing and testing, non-clinical study results, and clinical study reports. The quality section describes how the drug substance and product are made and controlled, while the clinical sections present trial results and risk management plans. Regulatory affairs professionals coordinate authors, check cross-references and ensure that the submission is consistent, complete and traceable to source data. Gaps often cause delays or requests for additional information.
An adverse event is any untoward medical occurrence in a participant, whether or not it is thought to be related to the product. Investigators record each event with its onset, severity, seriousness, and their assessment of causality. An event is classed as serious if it results in death, is life-threatening, requires hospitalization, causes disability or is otherwise significant. Serious adverse events that may be related to the product must be reported to the sponsor within short, defined timelines, and the sponsor then reports to regulators and ethics committees as required. Prompt, accurate reporting allows safety signals to be detected early, which protects current and future participants.
Pharmacovigilance is the science and activity of detecting, assessing, understanding and preventing adverse effects or other drug-related problems. Clinical trials are limited in size and duration, so rare or delayed reactions often emerge only after many patients have used a product in everyday practice. After approval, companies and regulators collect reports from clinicians, patients and published literature, and they analyze these to detect safety signals. Actions may include label changes, additional warnings, restricted use or withdrawal. Periodic safety reports and risk management plans document the ongoing monitoring. Effective pharmacovigilance therefore depends on consistent reporting and careful interpretation of imperfect data.
Statistical analysis plans are written before data are unblinded so that the questions, endpoints, populations and tests are fixed in advance. This protects against outcome switching, selective reporting and the temptation to search through data until a favorable result appears. Pre-specification also ensures that the sample size was calculated for the intended comparison, and that missing data and multiple comparisons are handled according to rules agreed upon in advance. When analysis is planned after results are known, p-values lose their meaning and the credibility of the findings falls. Regulators therefore expect the statistical analysis plan to be finalized and documented before the database is locked.
Randomization assigns participants to study groups by chance, which tends to balance known and unknown characteristics such as age, disease severity and prognosis across the groups. This makes differences in outcome more plausibly attributable to the intervention. Blinding, sometimes called masking, prevents participants, investigators and assessors from knowing which treatment was given, so that expectations do not influence reported symptoms, care decisions or outcome judgments. Double-blind designs are common for subjective outcomes. Where blinding is impossible, as in some surgical or behavioral studies, sponsors may use blinded outcome assessors instead. Careful documentation of the randomization system and unblinding procedures is essential for trial integrity.
Investigators remain accountable for the conduct of the study at their site, even when tasks are delegated to nurses, coordinators or other staff. They must maintain a delegation log showing who is authorized to perform which duties and ensure those people are trained on the protocol. Source documents, such as medical records and laboratory reports, must be accurate, contemporaneous and attributable, and case report forms must match them. Investigators keep study records for the required retention period and permit inspection by monitors, auditors and regulators. Poor documentation is one of the most common findings in inspections and can lead to rejected data or regulatory action.
Data management builds the systems and processes that turn raw trial information into reliable datasets. Teams design electronic data capture forms, write validation rules that flag implausible or missing values, and set up queries that prompt sites to correct discrepancies. Data are reviewed on a regular schedule, and medical coding standardizes adverse events and medications so they can be analyzed consistently. Before the database is locked, reconciliation confirms that safety data and other records agree. Good data management is planned early and documented in a data management plan. Clean data reduce analysis delays and support the credibility of the eventual regulatory submission.
Clinical research involves sensitive health information, so participant privacy must be protected at every stage. Trials typically assign each participant a unique study identifier so that case report forms do not display names, and investigators keep the link between identity and study records under secure control. Access to data is limited to authorized personnel, and electronic systems use authentication, encryption and audit trails. Data protection laws in different jurisdictions set requirements for consent to use data, transfers across borders and breach notification. Ethics committees and sponsors review data-sharing plans, and participants should be told clearly how their information will be used, stored and eventually shared.
Investigational products are not yet approved, so promotional claims about their benefits are generally prohibited. Companies may disseminate scientific information, such as results at professional meetings or in peer-reviewed journals, and they may answer unsolicited questions from healthcare professionals with accurate, balanced information. Advertising to the public about unapproved products is usually not permitted. Once a product is approved, promotional materials must match the approved label, be balanced in describing risks and benefits, and be substantiated by evidence. Regulatory affairs and medical review teams assess materials before release. Violations can lead to warning letters, corrective campaigns and penalties, so these boundaries shape day-to-day communication practice.
A quality management system is the set of documented policies, procedures, roles and records that ensures studies are conducted and reported to required standards. It includes standard operating procedures, training records, risk assessment, deviation and corrective action processes, and periodic internal audits. A risk-based approach focuses monitoring and oversight on the factors most likely to affect participant safety and key data. The system works best when problems are reported openly, analyzed for root causes and used to improve future practice rather than to assign blame. Sponsors and regulators look for evidence that the system operates in practice, not only that procedures exist on paper.
A regulatory inspection examines whether a trial was conducted and documented according to the protocol, applicable regulations and Good Clinical Practice. Inspectors typically review the delegation log, training records, informed consent forms, source documents, drug accountability and safety reporting, and they may interview staff and participants. Preparation involves keeping the trial master file complete and organized, conducting internal checks in advance, and ensuring staff can explain their roles clearly. Staff should answer questions honestly and provide requested records promptly. Discrepancies found during inspections are recorded in an inspection report, and the site may need a formal response with corrective and preventive actions.
Regulatory requirements differ across countries and change over time, so teams need systematic ways to monitor them. They subscribe to official guidance updates, follow regulator announcements, attend consultations and maintain country-specific requirement matrices. Many organizations assign regional experts who interpret new guidance for their teams and assess its impact on active programs. Tracking includes requirements for clinical trial authorization, labeling, manufacturing, advertising and post-market reporting. Because interpretation can be complex, teams often seek advice from legal counsel and agency contacts when rules are ambiguous. Regular training and documented impact assessments help ensure that changes are applied consistently across ongoing studies.
Regulators assess whether the benefits of a product outweigh its risks for the intended population and condition. The judgment considers the size and clinical importance of the observed benefit, the seriousness and frequency of known harms, the availability of alternative treatments and the uncertainty in the evidence. A product for a life-threatening disease with no alternatives may be approved on evidence that would be insufficient for a minor symptom. Regulators may require a risk management plan, restrictions on use or further studies after approval. This assessment is inherently judgment-based, and reasonable experts can disagree, so transparent presentation of data and uncertainty is important in submissions.
Real-world evidence is clinical information derived from routine care, such as electronic health records, registries and insurance claims. It can complement trials by showing how a product performs in older patients, people with multiple conditions or wider clinical settings that trials often exclude. It can also support long-term safety monitoring. Its limitations include missing or inconsistent data, selection bias, confounding by indication and variable outcome definitions. Regulators increasingly consider it, but usually with careful study design, pre-specified analyses and assessment of data quality. Real-world evidence is therefore a valuable supplement that requires rigorous methods rather than a replacement for controlled comparisons.